AbbVie (ABBV) Income from Non-Controlling Interests (2020 - 2026)
AbbVie (ABBV) reported Income from Non-Controlling Interests of $2.0 million for Q1 2026, down 33.33% year-over-year from $3.0 million in Q1 2025, and up 300.0% quarter-over-quarter from -$1.0 million in Q4 2025.
AbbVie (ABBV) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
AbbVie (ABBV) has 7 years of Income from Non-Controlling Interests data on file, last reported at $2.0 million in Q1 2026.
- Income from Non-Controlling Interests for Q1 2026 came in at $2.0 million, down 33.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.0 million (down 25.0% YoY), and the FY2025 annual result was $7.0 million, down 12.5% from the prior year.
- Income from Non-Controlling Interests advanced to $2.0 million in Q1 2026 per ABBV's latest filing, from -$1.0 million in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $4.0 million in Q2 2022 and troughed at -$1.0 million in Q4 2022.
- A 5-year average of $2.1 million and a median of $3.0 million in 2022 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2022 and 2023: Income from Non-Controlling Interests plunged 200.0% in 2022, then soared 300.0% in 2023.
- A 5-year view of Income from Non-Controlling Interests shows it stood at -$1.0 million in 2022, then soared by 300.0% to $2.0 million in 2023, then sank by 150.0% to -$1.0 million in 2024, then changed by 0.0% to -$1.0 million in 2025, then soared by 300.0% to $2.0 million in 2026.
- Business Quant data shows ABBV's Income from Non-Controlling Interests at $2.0 million in Q1 2026, -$1.0 million in Q4 2025, and $2.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | 2.48 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | 2.00 Mn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | -3.00 Mn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | - |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | 8.00 Mn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | 1.00 Mn |
| 10 | Novartis Ag | 112.59 Bn | 111.90 Bn | - | 415.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.00 Mn |
| Dec 31, 2025 | -1.00 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | 3.00 Mn |
| Mar 31, 2025 | 3.00 Mn |
| Dec 31, 2024 | -1.00 Mn |
| Sep 30, 2024 | 3.00 Mn |
| Jun 30, 2024 | 3.00 Mn |
| Mar 31, 2024 | 3.00 Mn |
| Dec 31, 2023 | 2.00 Mn |
| Sep 30, 2023 | 3.00 Mn |
| Jun 30, 2023 | 3.00 Mn |
| Mar 31, 2023 | 2.00 Mn |
| Dec 31, 2022 | -1.00 Mn |
| Sep 30, 2022 | 3.00 Mn |
| Jun 30, 2022 | 4.00 Mn |
| Mar 31, 2022 | 3.00 Mn |
| Dec 31, 2021 | 1.00 Mn |
| Sep 30, 2021 | 1.00 Mn |
| Jun 30, 2021 | 3.00 Mn |